Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study

Rhea-AI Summary

Inhibrx Biosciences (INBX) will host a live webcast on September 8, 2026 at 5:00 a.m. Pacific Time to present primary endpoint results from the randomized, controlled Phase 2 HexAgon study of INBRX-106 in first-line PD-L1 positive metastatic or unresectable recurrent head and neck squamous cell carcinoma.

The study evaluates INBRX-106, a hexavalent OX40 agonist, plus pembrolizumab versus pembrolizumab monotherapy. Investors can join via webcast or toll-free dial-in, and a replay with slides will be available on the company’s website for 60 days.

Argus Sep 8 session 61 alerts

-5.64% close to close 56.7x rel. volume Open Argus

Details

Market move: INBX -5.64% in the Sep 8 session. Phase 2 clinical data

+7.2% Peak Tracked

-25.7% Trough Tracked

$2.00B Mkt Cap at Peak Alert

On Sep 8, the first trading day after this news, INBX closed 5.64% below the previous close. Argus tracked a peak move of +7.2% during that session. Argus tracked a trough of -25.7% from its starting point during tracking. Our momentum scanner recorded 61 alerts for this stock that day. Relative volume reached 56.7x the daily average during tracking.

Data tracked by StockTitan Argus for the Sep 8 session.

Key Figures

Trial phase: Phase 2 Webcast date: September 8, 2026 Webcast time: 5:00 a.m. Pacific Time +2 more

Trial phase

Phase 2

HexAgon study primary endpoint results

Webcast date

September 8, 2026

Primary endpoint results presentation

Webcast time

5:00 a.m. Pacific Time

September 8, 2026 event

PD-L1 threshold

CPS ≥ 20

Treatment-naïve first-line HNSCC patients

Webcast availability

60 days

Availability following the event

Previous Clinical trial Reports

4 past events · Latest: Jun 15

Same Type 4 events

1. Jun 15

   BLA acceptance

   24h Move

   +1.4%

   FDA accepted the ozekibart BLA and assigned an April 2027 PDUFA goal date.

2. May 11

   Phase 2 data

   24h Move

   -5.0%

   Interim INBRX-106 data showed higher response rates versus pembrolizumab monotherapy.

3. Oct 23

   Topline trial results

   24h Move

   +102.0%

   Ozekibart topline results showed progression-free survival and disease-control advantages.

4. Jan 21

   Phase 1 data

   24h Move

   -4.2%

   Preliminary colorectal cancer data included complete and partial responses.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

hnscc, ox40 agonist, pd-l1, treatment-naïve

4 terms

hnscc medical

"Head and Neck Squamous Cell Carcinoma (HNSCC)"

HNSCC stands for head and neck squamous cell carcinoma, a type of cancer that starts in the flat lining cells that cover the surfaces of the mouth, throat and related structures. It matters to investors because treatments, clinical trial results, regulatory approvals or changes in diagnosis rates can directly affect the commercial prospects and valuation of companies developing therapies or diagnostics for this disease—think of it as a market signal tied to demand for specific medical products.

ox40 agonist medical

"a hexavalent OX40 agonist"

An OX40 agonist is a drug that activates the OX40 protein on immune cells to strengthen the body's T‑cell response, similar to pressing a gas pedal to make immune cells work harder. Investors watch these drugs because they are a form of immunotherapy being tested to treat cancers and immune diseases; positive clinical results can greatly increase a developer's value, while failures or safety concerns can reduce it.

pd-l1 medical

"first-line patients with treatment-naïve, PD-L1 positive"

PD-L1 is a protein found on the surface of some cells that acts like a stop sign for the immune system, telling certain immune cells to back off. It matters to investors because many cancer drugs and diagnostic tests target or measure PD-L1 to unlock immune responses or predict which patients will benefit, affecting clinical success, regulatory approval, and potential sales in the oncology market.

treatment-naïve medical

"patients with treatment-naïve, PD-L1 positive"

Patients described as treatment-naïve have not previously received the therapy being studied or other prior treatments for the same condition, so their bodies are ‘untouched’ by those drugs. For investors, this matters because results in a treatment-naïve group show how a therapy performs without prior drug effects, influence trial design and regulatory labeling, and help estimate the size and profile of the initial market—like testing a new seed in a garden that has never been treated before.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

– Event to be webcast live on Tuesday, September 8 ^th at 5:00 a.m. PT –

SAN DIEGO, Sept. 4, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced that it will host a live webcast presentation on Tuesday, September 8, 2026 at 5:00 a.m. Pacific Time, to provide primary endpoint results from the randomized and controlled Phase 2 portion of the HexAgon study, which is evaluating the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab (the combination arm) versus pembrolizumab monotherapy (the control arm) in first-line patients with treatment-naïve, PD-L1 positive (CPS ≥ 20) metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma (HNSCC).

Investors may join via the web: https://app.webinar.net/4712m15mpwW or may listen to the call by dialing (1-888-880-3330). Please refer to Inhibrx Biosciences, Inc. or the conference ID 6981384 when calling in. The webcast will also include a slide presentation of the data, which is also incorporated into the Company's investor deck accessible at https://inhibrx.com/inhibrx-biosciences-inc-investors/. Following the webcast, the presentation may be accessed through a link on the "Events and Presentations" section of Inhibrx's website. The webcast will be available for 60 days following the event. Inhibrx will also update its corporate presentation within the "Investors" section of its website at www.inhibrx.com.

About INBRX-106

INBRX-106 is a hexavalent agonist targeting OX40 (CD134), a costimulatory receptor on T-cells. Utilizing Inhibrx's proprietary single-domain antibody (sdAb) platform, INBRX-106 is designed to achieve the high-order receptor clustering necessary for robust T-cell activation and survival, a feat that has eluded traditional bivalent antibody approaches.

About Inhibrx Biosciences, Inc.

Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx Biosciences utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Inhibrx Biosciences was incorporated in January 2024 as a direct, wholly-owned subsidiary of Inhibrx, Inc. Prior to the sale of Inhibrx, Inc. and the INBRX-101 program to Sanofi S.A., Inhibrx Biosciences acquired certain corporate infrastructure and other assets and liabilities through a series of internal restructuring transactions effected by Inhibrx, Inc. Inhibrx, Inc. also completed a distribution to holders of its shares of common stock of 92% of the issued and outstanding shares of Inhibrx Biosciences. Following such transactions, Inhibrx Biosciences' current clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what we believe to be the most appropriate agonist function. For more information, please visit www.inhibrx.com.

Investor and Media Contact:

Kelly Deck, CFO
ir@inhibrx.com
858-795-4260

View original content to download multimedia:https://www.prnewswire.com/news-releases/inhibrx-to-host-webcast-presentation-to-provide-primary-endpoint-results-for-inbrx-106-phase-2-first-line-hnscc-study-302869703.html

SOURCE Inhibrx Biosciences, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is the Inhibrx INBX webcast for INBRX-106 Phase 2 HexAgon HNSCC results?

The live webcast presentation is scheduled for Tuesday, September 8, 2026 at 5:00 a.m. Pacific Time. Inhibrx will present primary endpoint results from the randomized, controlled Phase 2 HexAgon study of INBRX-106 in first-line PD-L1 positive metastatic or unresectable recurrent HNSCC.

How can investors access the Inhibrx INBX HexAgon Phase 2 results webcast online?

Investors may join the webcast by visiting https://app.webinar.net/4712m15mpwW. The webcast will include a slide presentation of the HexAgon Phase 2 data and will also be incorporated into the company’s investor deck available through the Investors section of the Inhibrx website.

What is the dial-in information for the Inhibrx INBX INBRX-106 Phase 2 webcast?

Participants may listen to the call by dialing 1-888-880-3330. Callers should refer to Inhibrx Biosciences or provide the conference ID 6981384 when joining the webcast by phone.

Will a replay of the Inhibrx INBX HexAgon Phase 2 webcast be available?

Yes. Following the live event, the presentation may be accessed via a link in the “Events and Presentations” section of the Inhibrx website. The webcast replay, including the slide presentation, will be available for 60 days after the event.

What study will be discussed in the Inhibrx INBX September 8, 2026 webcast?

The webcast will cover primary endpoint results from the Phase 2 portion of the HexAgon study, which evaluates INBRX-106, a hexavalent OX40 agonist, plus pembrolizumab versus pembrolizumab alone in first-line treatment-naïve, PD-L1 positive (CPS ≥ 20) metastatic or unresectable recurrent head and neck squamous cell carcinoma.